Clinical Safety

Ivan Kairatov brings a biopharma lens to one of the most sensitive decisions in pediatrics: when to give the first hepatitis B vaccine. With a research-and-development background rooted in tech and innovation, he translates probabilistic modeling, clinical epidemiology, and practical workflows into

Swift regulatory action upended a fragile corner of San Antonio’s behavioral health system when federal officials moved to terminate Medicare and Medicaid participation for a major psychiatric hospital that treats children, adolescents, adults, veterans, and people with substance use disorders,

Admission to GLP-1 therapy once crawled through a maze of clinic calendars, phone tag, and insurer scripts, but a wave of purpose-built telehealth apps has turned that maze into a guided lane on a phone that now functions as both navigator and engine. The change was not merely cosmetic. Adaptive

Clinic days often hinge on one question patients ask with a mix of hope and hesitation: is there a pill that can match the clearing power of injections without the needles, the storage hassles, or the crowded appointment calendar. That answer just shifted as the FDA cleared Johnson & Johnson’s

Relentless rises in drug-resistant infections have turned routine care into a negotiation with risk that standard antibiotics too often lose, and the search for smarter countermeasures has shifted to tools built by biology itself. Bacterial extracellular vesicles (BEVs) sit at that inflection

The rapid proliferation of computational intelligence in pharmaceutical development has reached a critical juncture where traditional manual oversight methods are struggling to keep pace with the speed of machine learning integration. On April 20, 2026, Advarra unveiled a comprehensive framework